Hot Keywords
metabolic syndrome kidney atherosclerosis endocrine disorder NAFLD diabetes MAFLD adipose tissue obesity obesity metabolism fatty liver steatosis fibrosis cardiovascular insulin resistance hypertension metabolomics precision medicine hypertriglyceridemia


Special Interview with Dr. Fulvio Lonardo

Published on: 21 Jul 2022 Viewed: 154

On July 15, we are delighted to have a special interview with our journal author, Dr. Fulvio Lonardo, from the Department of Pathology, Wayne State University School of Medicine, Harper University Hospital, and Karmanos Cancer Institute, Detroit, MI, USA.

This interview is initiated based on a review article Metabolism and cancer-select topics on Metabolism and Target Organ Damage (M&TOD). Dr. Lonardo emphasized that from an evolutionary standpoint, increased cancer incidence is associated with increased metabolic rates across species.

The Editor-in-Chief, Dr. Amedeo Lonardo, had a brief discussion with Dr. Fulvio Lonardo and the full record of this interview can be found below.

Author's Biography

Dr. Lonardo graduated summa cum laude at the 2nd Medical School, Naples, Italy, pursued basic research at the NIH/NCI as a Fogarty fellow and completed his residency training in Surgical Pathology at the University of Rochester, NY, followed by fellowships in Oncologic Surgical Pathology and molecular biology at Memorial Sloan Kettering Cancer, NYC, NY.

He is Professor of Pathology at Harper University Hospital, Wayne State University Medical School, where he practices as a general surgical pathologist, with specialty interests in Head and Neck and Lung Pathology.

He lectures 2nd year medical students on pathological basis of cancer, neoplastic and non-neoplastic lung pathology, and surgical pathology residents on lung and salivary gland pathology.

Research Interests
Together with S. Sheng, PhD. Dr. Lonardo has found that an exclusively nuclear expression, compared to a combined nuclear-cytoplasmic expression of the tumor suppressor protein maspin, is common in adenocarcinoma, but not in squamous cell carcinoma of the lung. In addition, in limited stage adenocarcinoma nuclear maspin is linked with favorable clinical-pathological variables, including improved survival. These data, along with in vitro evidence, support the hypothesis that maspin's tumor suppressor ability depends on its nuclear localization.

He has been involved in studies on serum markers of mesothelioma (N Engl J Med, 2005. 353(15):1564-73).

He is currently involved with Ann Schwartz, PhD, in epidemiological studies. to address the hypothesis that that there may be differences the biology of lung cancer between African American vs. white patients and, with Dr. G. Bepler,MD.PhD, in studies on the biochemical basis of chemotherapy resistance, using an in vitro model of lung cancer.

© 2016-2022 OAE Publishing Inc., except certain content provided by third parties